Study probes host-directed approach to P. multocida vascular injury
Bottom line
Version 1
Researchers reporting in Animals say 18β-glycyrrhetinic acid, a bioactive compound derived from licorice, reduced Pasteurella multocida-associated vascular injury in experimental work by blocking PARP1-driven NF-κB p65 movement into the nucleus, a key step in inflammatory signaling. The study builds on earlier work from the same research group showing the compound could dampen P. multocida-triggered endothelial inflammation in porcine vascular endothelial cells and improve outcomes in a mouse model of vascular inflammatory injury. P. multocida is a zoonotic pathogen and an important contributor to respiratory disease in pigs, where it is usually recognized as part of the porcine respiratory disease complex rather than as a primary pathogen in most modern production settings. (pubmed.ncbi.nlm.nih.gov)
Why it matters: For veterinary professionals, the paper adds another mechanistic layer to a growing preclinical literature around host-directed approaches for P. multocida, focusing not on direct bacterial killing but on limiting vascular and inflammatory damage. That’s relevant because current control in pigs still leans on management, biosecurity, antimicrobials, and vaccines, while inflammatory injury can continue even when the infection itself is being treated. Still, this remains early-stage research, not a clinical product announcement, and the available evidence is preclinical rather than field-based. (merckvetmanual.com)
What to watch: The next step is whether these findings move into pharmacodynamic, safety, dosing, and field-efficacy studies in pigs, where any practical veterinary use would have to be established. (tandfonline.com)
Key facts
- Study
- Experimental work in Animals
- Compound
- 18β-glycyrrhetinic acid
- Pathogen
- Pasteurella multocida
- Main finding
- Reduced P. multocida-associated vascular injury
- Proposed mechanism
- Blocked PARP1-driven NF-κB p65 nuclear translocation
- Species relevance
- Important contributor to respiratory disease in pigs
- Prior study
- Reduced P. multocida-induced endothelial inflammation in porcine vascular endothelial cells
- Earlier mouse study
- Improved outcomes in a mouse model of vascular inflammatory injury
- Clinical stage
- Preclinical, not a veterinary product announcement
Version 2
A new study in Animals examines whether 18β-glycyrrhetinic acid can blunt the vascular damage caused by Pasteurella multocida, a zoonotic pathogen tied to severe respiratory disease and, in some cases, septicemic disease in pigs. According to the study summary provided and related prior publications from the same research line, the compound appears to attenuate injury by inhibiting PARP1/NF-κB p65 nuclear translocation, a signaling event associated with inflammatory activation and tissue damage. (pmc.ncbi.nlm.nih.gov)
That question fits into a longer arc of work on P. multocida pathogenesis. In pigs, P. multocida is usually considered part of the porcine respiratory disease complex and most often acts as an opportunistic or secondary pathogen, although primary fibrinous pneumonia and septicemia can occur. Merck Veterinary Manual notes that control still centers on good management, biosecurity, and antimicrobials, with antimicrobial resistance also reported. (merckvetmanual.com)
The new paper also appears to extend a sequence of earlier studies from the same investigators. In 2023, they reported that 18β-glycyrrhetinic acid reduced P. multocida-induced vascular endothelial inflammation in porcine iliac artery endothelial cells through PARP1-mediated NF-κB and HMGB1 signaling suppression. In a 2025 mouse study, the group reported improved survival, better hematologic and biochemical markers, and less vascular inflammatory injury after treatment with the same compound. (pubmed.ncbi.nlm.nih.gov)
Taken together, the research suggests the team is narrowing from a broader anti-inflammatory signal toward a more specific mechanism involving PARP1 and NF-κB p65 nuclear translocation. That matters scientifically because vascular injury is a notable feature of severe P. multocida disease, including hemorrhagic lung lesions and systemic inflammatory changes described across the literature. Experimental and pathology reports in pigs have documented vascular involvement, including vessel wall injury and septicemic presentations. (pmc.ncbi.nlm.nih.gov)
I didn’t find a clear independent expert reaction or company announcement tied specifically to this Animals paper. What the broader literature does show is continuing interest in glycyrrhetinic acid as a pharmacologically active natural compound with anti-inflammatory effects across multiple disease models, and in P. multocida specifically as a possible adjunctive, host-response-modulating approach rather than a replacement for standard infectious disease control. That interpretation is an inference from the available studies, not a stated clinical recommendation. (mdpi.com)
Why it matters: For veterinarians and animal health teams, this is best read as mechanism-rich translational research, not practice-changing evidence. If the pathway holds up in pigs, it could eventually support adjunct strategies aimed at reducing endothelial and vascular damage during severe pasteurellosis or mixed respiratory disease. But there’s still a large gap between cell and mouse findings and anything usable in commercial swine medicine, including dose selection, formulation, safety, residue considerations, efficacy under field conditions, and how such an approach would fit alongside antimicrobials, vaccination, and herd-level prevention. (merckvetmanual.com)
There’s also a practical stewardship angle. Because P. multocida disease in pigs often emerges in the context of broader respiratory complex pressure, therapies that reduce host tissue injury without relying solely on direct antimicrobial effect are conceptually attractive. Even so, no evidence from the sources reviewed shows that 18β-glycyrrhetinic acid is ready for veterinary use in pigs, and earlier authors have explicitly said pharmacodynamic and animal therapeutic trials are still needed. (merckvetmanual.com)
What to watch: Watch for full publication details for the Animals paper, plus any follow-on pig studies that test dosing, safety, and real-world efficacy in P. multocida challenge or field settings before this line of work can move from bench interest to veterinary relevance. (pmc.ncbi.nlm.nih.gov)